Moreover, Jiang and colleagues demonstrated that introducing an inhibitor of rate ido enzyme IDO-1 reversed behavioral changes in the BDL rats, thus highlighting the therapeutic potential of modulating KP activity for patients with HE. The gene discussed is NPPA; the disease is hereditary elliptocytosis.